Sponsored by
Last year, there was a lot of excitement around CAR T-cell therapy for recurrent glioblastoma (GBM) after a few early trials showed tumors shrinking. Many in the field were cautious, though, because the responses were transient. New results from a Phase 1 dose escalation CAR T trial for recurrent GBM at the University of Pennsylvania are helping to shed light on the potential for this therapy. Using dual-target CAR-T cells designed to hit two proteins found on GBM cells (EGFR and IL13Ra2), researchers saw tumors shrink in 62% of patients (8 of 13) who still had visible disease after surgery. Survival data for all patients treated thus far (n=18) is still accumulating, but several patients in the trial have lived 12 months or longer after receiving treatment, and one patient has had stable disease for over 16 months. The early cohorts in this study received only one CAR T-cell infusion, but future cohorts may receive more than one. There are also plans to investigate this treatment in the newly diagnosed setting. We'll be keeping an eye out for further updates from this study!